Brokerages expect CorMedix Inc (NASDAQ:CRMD) to announce earnings of ($0.25) per share for the current quarter, according to Zacks. Two analysts have provided estimates for CorMedix’s earnings. CorMedix reported earnings of ($0.55) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 54.5%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 13th.

According to Zacks, analysts expect that CorMedix will report full year earnings of ($0.98) per share for the current year. For the next fiscal year, analysts expect that the firm will post earnings of ($1.64) per share, with EPS estimates ranging from ($2.26) to ($1.01). Zacks’ EPS calculations are an average based on a survey of research analysts that cover CorMedix.

CRMD traded down $0.04 during trading on Friday, reaching $8.16. The company’s stock had a trading volume of 999 shares, compared to its average volume of 492,207. CorMedix has a 52-week low of $1.90 and a 52-week high of $13.70. The company’s fifty day moving average price is $8.82 and its 200-day moving average price is $6.57.

CorMedix Company Profile

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Recommended Story: How a Put Option Works

Get a free copy of the Zacks research report on CorMedix (CRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.